Wild Apricot



MSHPNovember 2, 2019Fall Meeting – Bangor MeTechnician HandoutImpact of Clinician Burnout on Patient Safety: Journey to a Resilient & Thriving Healthcare WorkforcePaul W. Abramowitz, PharmD., Sc.D (HON) FASHP, ASHP’s CEO—Key Note Address0837-9999-19-256-L05-TDefine burnout, well-being, and resilienceExplain why clinician burnout is a patient care and healthcare workforce problemDiscuss the U.S. National Academy of Medicine Clinician Well-Being and Resilience Action CollaborativeIdentify strategies to improve well-being and resilience in the healthcare workforce AUC: It’s Easy as 1,2,3Brian McCullough, PharmD, BCPS0837-9999-19-260-L01-TName a type of bacteria that is killed by vancomycinList patient factors that may change how vancomycin is dosedRecognize the current preferred way to dose vancomycin Updates on ASHPs Summer MeetingKathryn Sawicki, PharmDMatthew Christie, PharmD0837-9999-19-265-L04-TReview the policies presented for change at ASHPs Summer MeetingAssess policies and changes that were extensively discussedExplain the use of policies in the national law making processIdentify policies up for future discussion Harm and Reducing Maine Overdose Deaths: A Naloxone and SUD Stigma Primer for Pharmacy ProfessionalsStephanie Nichols, PharmD, BCPS, BCPP, FCCPKenneth McCall, PharmD, BSPharm, BCGP, FAPhA0837-9999-19-262-L01-TRecognize the impact of the opioid epidemic in MaineIdentify stigmatizing terms related to patients with substance use disorder (SUD) and select appropriate alternativesRecognize the impact of stigmatizing terminology on patient careRecognize non-stigmatizing language to a scenario involving a patient with SUDReview SUD to other medical/psychiatric diseases and describe the harm reduction approach to careDescribe the mechanism of naloxone and its place in therapyIdentify persons at risk of an opioid overdose and signs of an overdoseSummarize the characteristics of the various naloxone formulations including administration techniquesDiscuss critical patient education points regarding opioid overdose and naloxone: Current Trends and Future DirectionsChristopher Peric, PharmD, BCPS0837-9999-19-258-L01-TReview biosimilar regulatory and development pathwaysDescribe current formulary management approaches for biosimilarsDiscuss clinical and financial considerations for future biosimilar use ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download